New antibiotic shows promise against Drug-Resistant lung bug
NCT ID NCT07372781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new antibiotic called contezolid against a hard-to-treat lung infection caused by Mycobacterium abscessus. Twenty-four adults will take either contezolid or an older drug, linezolid, for 14 days. Researchers will measure how quickly the drug kills the bacteria in sputum samples to see if contezolid works as well or better than the current treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
contezolid (an antibiotic)
What this could lead to
If contezolid works better than linezolid, it could offer a new treatment option for hard-to-treat Mycobacterium abscessus lung infections.
What could go wrong
This is a small, early-phase trial with only 24 people. The drug may not prove effective or safe in larger studies. Side effects are possible, and the infection often requires long-term therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis & Thoracic Tumor Research Institute
Beijing, Beijing Municipality, 101149, China